A Multi-centre Study to Assess the Safety, Tolerability, and Pharmacokinetics of Capivasertib (AZD5363) in Combination With Novel Agents in Patients With Metastatic Prostate Cancer

Completed · Phase 1

Conditions studied: Prostate Cancer

In brief

This is a Phase Ib, open-label, multi-centre study to determine the safety, tolerability and pharmacokinetics (PK) of capivasertib when given in combination with novel agents (enzalutamide or abiraterone) to inform the selection of capivasertib dose regimens for each combination for further clinical evaluation when given to patients with metastatic castration resistant prostate cancer (CRPC). The study design allows an exploration of different doses with intensive safety monitoring to ensure the safety of the patients.

Key facts

Study ID: NCT04087174
Run by: AstraZeneca
People needed: 27
Starts: 2019-08-05
Expected to finish: 2021-06-22
Last updated by the study team: 2022-07-13

Who can join

Age: 18 and older, up to 130. Sex: male. Healthy volunteers: not accepted.

You may qualify if…

Capable of giving signed informed consent which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol prior to any mandatory study-specific procedures, sampling, and analyses.
Males aged 18 years and older at the time of signing the ICF.
Patients with documented evidence of metastatic CRPC who have had at least one line of systemic therapy for metastatic CRPC (either chemotherapy or an novel hormonal agents [NHA]) or for whom no alternative approved therapy is available.
World Health Organization (WHO) performance status 0 to 2 with no deterioration over the previous 2 weeks and minimum life expectancy of 12 weeks, as assessed at day 1.
Patients must be able to swallow and retain oral medication.
Agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive measures, and agreement to refrain from donating sperm.
Sterilisation (with the appropriate post-vasectomy documentation of the absence of sperm in the ejaculate).
Patients should use barrier contraception (ie, condoms) from the time of screening until 16 weeks after discontinuation of study treatment. It is not known whether the preclinical changes seen in the male animal reproductive organs, after treatment with capivasertib, will be fully reversible or will permanently affect the ability to produce healthy sperm following treatment. Therefore, if patients wish to father children they should be advised to arrange for collection of sperm samples prior to the start of study treatment.

You may not qualify if…

Previous enrolment in the present study.
Prior enzalutamide therapy in the last 8 weeks.
Treatment with any of the following:
Nitrosourea or mitomycin C within 6 weeks of the first dose of study treatment.
Any investigational agents or study drugs from a previous clinical study within 30 days of the first dose of study treatment.
Any other chemotherapy, immunotherapy, immunosuppressant medication (other than corticosteroids) or anti-cancer agents within 3 weeks of the first dose of study treatment, except hormonal therapy with luteinising hormone-releasing hormone (LHRH) analogues for medical castration in patients with prostate cancer, which are permitted.
Potent inhibitors or inducers or substrates of CYP3A4 within 2 weeks before the first dose of study treatment (3 weeks for St. John's wort) or sensitive substrates of CYP3A4, CYP2C9 and/or CYP2D6 with a narrow therapeutic window within 1 week prior to the first dose of study treatment.
Major surgery (excluding placement of vascular access) within 4 weeks of the first dose of study treatment.
Radiotherapy with a wide field of radiation within 4 weeks of the first dose of study treatment.
Clinically significant abnormalities of glucose metabolism as defined by any of the following:
Diabetes mellitus Type I or Type II requiring insulin treatment.
HbA1c ≥8.0% (63.9 mmol/mol).
Spinal cord compression or brain metastases unless asymptomatic, treated and stable and not requiring steroids for at least 4 weeks prior to start of study treatment.
Past medical history of interstitial lung disease, drug-induced interstitial lung disease, radiation pneumonitis which required steroid treatment, or any evidence of clinically active interstitial lung disease.
As judged by the investigator, any evidence of severe or uncontrolled systemic diseases, including uncontrolled hypertension, active bleeding diatheses, or active infection including hepatitis B, hepatitis C, and human immunodeficiency virus. Screening for chronic conditions is not required.
Any of the following cardiac criteria:
Mean resting corrected QT interval (QTc) >470 milliseconds obtained from 3 consecutive ECGs.
Any clinically important abnormalities in rhythm, conduction, or morphology of a resting ECG (eg, complete left bundle branch block, 3rd degree heart block).
Any factors that increase the risk of QTc prolongation or risk of arrhythmic events such as heart failure, hypokalaemia, potential for torsades de pointes, congenital long QT syndrome, family history of long QT syndrome or unexplained sudden death under 40 years-of-age, or any concomitant medication known to prolong the QT interval.
Clinically significant heart disease as evidenced by myocardial infarction or arterial thrombotic events in the past 6 months, severe or unstable angina, or New York Heart Association NYHA Class II to IV heart failure or cardiac ejection fraction measurement of <50%.
Experience of any of the following procedures or conditions in the preceding 6 months: coronary artery bypass graft, angioplasty, vascular stent, myocardial infarction, angina pectoris, congestive heart failure NYHA ≥2.
Uncontrolled hypotension defined as - systolic BP <90 mmHg and/or diastolic BP<50 mmHg.
Uncontrolled hypertension defined as - systolic BP >160 mmHg and/or diastolic BP ≥95 mmHg.
Cardiac ejection fraction outside institutional range of normal or <50% (whichever is higher) as measured by echocardiogram (or multi gated acquisition scan (MUGA), if an echocardiogram cannot be performed or is inconclusive).
With the exception of alopecia, any unresolved toxicities from prior therapy greater than Common Terminology Criteria for Adverse Event (CTCAE) grade 1 at the time of starting study treatment.

Where it is running

Research Site — Indianapolis, Indiana, United States
Research Site — Omaha, Nebraska, United States
Research Site — White Plains, New York, United States
Research Site — Gettysburg, Pennsylvania, United States
Research Site — Myrtle Beach, South Carolina, United States
Research Site — Barcelona, Spain

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.